CN Patent

CN103655464A — 供注射用的盐酸纳美芬药物组合物

Assigned to TIANJIN SONGRUI MEDICAL TECHNOLOGY CO LTD · Expires 2014-03-26 · 12y expired

What this patent protects

本发明涉及医药领域中的药品，尤其是涉及一种稳定性好的供注射用的盐酸纳美芬药物组合物及其制备方法，作为新一代阿片受体拮抗剂，用于完全或部分逆转阿片类药物的作用，包括由天然或合成的阿片类药物引起的呼吸抑制；用于已知或疑似阿片类药物过量的治疗。

USPTO Abstract

本发明涉及医药领域中的药品，尤其是涉及一种稳定性好的供注射用的盐酸纳美芬药物组合物及其制备方法，作为新一代阿片受体拮抗剂，用于完全或部分逆转阿片类药物的作用，包括由天然或合成的阿片类药物引起的呼吸抑制；用于已知或疑似阿片类药物过量的治疗。

Drugs covered by this patent

nalmefene-hydrochloride (NALMEFENE HYDROCHLORIDE)

Patent Metadata

Patent number: CN103655464A
Jurisdiction: CN
Classification: —
Expires: 2014-03-26
Drug substance claim: No
Drug product claim: No
Assignee: TIANJIN SONGRUI MEDICAL TECHNOLOGY CO LTD
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.